MA53550A - Procédés alternatifs pour la préparation de tubulysines et intermédiaires de celles-ci - Google Patents

Procédés alternatifs pour la préparation de tubulysines et intermédiaires de celles-ci

Info

Publication number
MA53550A
MA53550A MA053550A MA53550A MA53550A MA 53550 A MA53550 A MA 53550A MA 053550 A MA053550 A MA 053550A MA 53550 A MA53550 A MA 53550A MA 53550 A MA53550 A MA 53550A
Authority
MA
Morocco
Prior art keywords
tubulysins
intermediates
preparation
alternative methods
alternative
Prior art date
Application number
MA053550A
Other languages
English (en)
Inventor
Wendel Doubleday
Qingwu Jin
Kun-Liang Wu
Original Assignee
Seagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seagen Inc filed Critical Seagen Inc
Publication of MA53550A publication Critical patent/MA53550A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26Acyclic or carbocyclic radicals, substituted by hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1024Tetrapeptides with the first amino acid being heterocyclic
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA053550A 2018-09-07 2019-09-06 Procédés alternatifs pour la préparation de tubulysines et intermédiaires de celles-ci MA53550A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862728639P 2018-09-07 2018-09-07

Publications (1)

Publication Number Publication Date
MA53550A true MA53550A (fr) 2021-12-15

Family

ID=68000124

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053550A MA53550A (fr) 2018-09-07 2019-09-06 Procédés alternatifs pour la préparation de tubulysines et intermédiaires de celles-ci

Country Status (17)

Country Link
US (1) US20230002440A1 (fr)
EP (1) EP3847161A1 (fr)
JP (1) JP7511543B2 (fr)
KR (1) KR20210073525A (fr)
CN (1) CN112996778A (fr)
AU (1) AU2019336231A1 (fr)
BR (1) BR112021004317A2 (fr)
CA (1) CA3111149A1 (fr)
EA (1) EA202190699A1 (fr)
IL (1) IL281090A (fr)
MA (1) MA53550A (fr)
MX (1) MX2021002570A (fr)
SA (1) SA521421375B1 (fr)
SG (1) SG11202102126VA (fr)
TW (1) TWI825169B (fr)
UA (1) UA128730C2 (fr)
WO (1) WO2020051503A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020482800B2 (en) * 2020-12-23 2025-08-21 Genequantum Healthcare (Suzhou) Co., Ltd. Novel isomeric compounds comprising a ring-opened thiosuccinimide group, an oligopeptide fragment and a chiral moiety
AU2022238571A1 (en) 2021-03-18 2023-09-14 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8980833B2 (en) * 2007-05-10 2015-03-17 R&D-Biopharmaceuticals Gmbh Tubulysine derivatives
IT1394860B1 (it) 2009-07-22 2012-07-20 Kemotech S R L Composti farmaceutici
CN108367043A (zh) 2015-12-04 2018-08-03 西雅图基因公司 季铵化的微管溶素化合物的缀合物
TW202428569A (zh) 2017-09-08 2024-07-16 美商思進公司 妥布賴森(tubulysins)及其中間產物之製備方法

Also Published As

Publication number Publication date
CN112996778A (zh) 2021-06-18
MX2021002570A (es) 2021-06-08
EA202190699A1 (ru) 2021-06-08
JP2021536475A (ja) 2021-12-27
KR20210073525A (ko) 2021-06-18
US20230002440A1 (en) 2023-01-05
TW202024043A (zh) 2020-07-01
AU2019336231A1 (en) 2021-03-18
SG11202102126VA (en) 2021-04-29
EP3847161A1 (fr) 2021-07-14
UA128730C2 (uk) 2024-10-09
WO2020051503A1 (fr) 2020-03-12
JP7511543B2 (ja) 2024-07-05
SA521421375B1 (ar) 2024-02-11
BR112021004317A2 (pt) 2021-05-25
IL281090A (en) 2021-04-29
TWI825169B (zh) 2023-12-11
CA3111149A1 (fr) 2020-03-12

Similar Documents

Publication Publication Date Title
MA51796A (fr) Procédés et compositions pour l'administration de protéines thérapeutiques
MA53445A (fr) Procédés et compositions pour la modification de plantes
EP3893655A4 (fr) Procédés pour la préparation d'un composition de protéines végétales
EP3774709A4 (fr) Procédés de réduction de l'inflammation du système digestif à l'aide d'inhibiteurs de hif-2-alpha
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
MA55082A (fr) Compositions, procédés, et kits pour l'administration de polyribonucléotides
MA43365A (fr) Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
EP3402483A4 (fr) Procédés et compositions pour l'activation de lymphocytes t gamma-delta
EP3328429A4 (fr) Peptides et anticorps pour l'élimination de biofilms
EP3488018A4 (fr) Procédés et compositions pour l'identification de protéines
EP3891272A4 (fr) Compositions et procédés d'immunothérapie
EP3833340A4 (fr) Compositions et procédés de traitement de la presbytie
EP3897717A4 (fr) Procédés de production d'anticorps hétérodimères
EP3450426A4 (fr) Procédé pour la synthèse de silodosine et d'un intermédiaire de celle-ci
EP3648773A4 (fr) Composés et procédés pour l'administration transmembranaire de molécules
EP3361864A4 (fr) Dispositifs et procédés pour la préparation d'échantillon biologique pour une procédure cryogénique
MA46431A (fr) Composés et procédés pour réduire l'expression de tau
MA53370A (fr) Procédé et intermédiaires pour la préparation de bilastine
MA42497A (fr) Procédés et compositions pour la régulation sélective de l'expression protéique
MA51307A (fr) Compositions laitières fermentées et procédés de préparation de celles-ci
MA71753A (fr) Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de guanylate cyclase soluble
EP3803416A4 (fr) Compositions et procédés de détection d'une lésion cérébrale traumatique
MA53550A (fr) Procédés alternatifs pour la préparation de tubulysines et intermédiaires de celles-ci
EP3902792A4 (fr) Procédé de préparation d'anthranilamides
IL272837A (en) A process for preparing tubolysins and their intermediates